[1] |
Strueby L, Thébaud B. Advances in bronchopulmonary dysplasia[J]. Expert Rev Respir Med, 2014, 8(3): 327-338.
|
[2] |
Brener Dik PH, Niño Gualdron YM, Galletti MF, et al. Bronchopulmonary dysplasia: incidence and risk factors[J]. Arch Argent Pediatr, 2017, 115(5): 476-482.
|
[3] |
Kiciński P, Ksiak M, Nowiczewski M, et al. Bronchopulmonary dysplasia in very and extremely low birth weight infants - analysis of selected risk factors[J]. Pol Merkur Lekarski, 2017, 42(248): 71-75.
|
[4] |
Voynow JA. " New" bronchopulmonary dysplasia and chronic lung disease[J]. Paediatr Respir Rev, 2017, 24(1): 17-18.
|
[5] |
Lal CV, Ambalavanan N. Biomarkers, early diagnosis, and clinical predictors of bronchopulmonary dysplasia[J]. Clin Perinatol, 2015, 42(4): 739-754.
|
[6] |
Rivera L, Siddaiah R, Oji-Mmuo C, et al. Biomarkers for bronchopulmonary dysplasia in the preterm infant[J]. Front Pediatr, 2016, 4: 33.
|
[7] |
Lal CV, Ambalavanan N. Cellular and humoral biomarkers of bronchopulmonary dysplasia[J]. Early Hum Dev, 2017, 105: 35-39.
|
[8] |
Miura T. Models of lung branching morphogenesis[J]. J Biochem, 2015, 157(3): 121-127.
|
[9] |
Hadchouel A, Franco-Montoya ML, Delacourt C. Altered lung development in bronchopulmonary dysplasia[J]. Birth Defects Res Part A Clin Mol Teratol, 2014, 100(3): 158-167.
|
[10] |
Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia[J]. Birth Defects Res Part A Clin Mol Teratol, 2014, 100(3): 145-157.
|
[11] |
Jobe AH. Mechanisms of lung injury and bronchopulmonary dysplasia[J]. Am J Perinatol, 2016, 33(11): 1076-1078.
|
[12] |
Silva DM, Nardiello C, Pozarska A, et al. Recent advances in the mechanisms of lung alveolarization and the pathogenesis of bronchopulmonary dysplasia[J]. Am J Physiol Lung Cell Mol Physiol, 2015, 309(11): L1239-L1272.
|
[13] |
Niedermaier S, Hilgendorff A. Bronchopulmonary dysplasia: an overview about pathophysiologic concepts [J]. Mol Cell Pediatr, 2015, 2(1): 2.
|
[14] |
Matsumura H, Ichiba H, Ohnishi S, et al. Histologic chorioamnionitis, amniotic fluid interleukin 6, krebs von den lungen 6, and transforming growth factor beta1 for the development of neonatal bronchopulmonary dysplasia[J]. Jpn Clin Med, 2017, 8: 1179066017696076.
|
[15] |
Wang KY, Huang XM, Lu H, et al. A comparison of KL-6 and clara cell protein as markers for predicting bronchopulmonary dysplasia in preterm infants[J]. Dis Markers, 2014, 2014: 736536.
|
[16] |
Dilli D, Özyazici A, Dursun A, et al. Predictive values of plasma KL-6 in bronchopulmonary dysplasia in preterm infants[J]. Turk J Med Sci, 2017, 47(2): 621-626.
|
[17] |
McAuley DF, Matthay MA. Clara cell protein CC16. A new lung epithelial biomarker for acute lung injury[J]. Chest, 2009, 135(6): 1408-1410.
|
[18] |
Guzmán-Bárcenas J, Calderón-Moore A, Baptista-González H, et al. Clara cell protein expression in mechanically ventilated term and preterm infants with respiratory distress syndrome and at risk of bronchopulmonary dysplasia: a pilot study[J]. Can Respir J, 2017, 2017: 8074678.
|
[19] |
Hendrix AY, Kheradmand F. The role of matrix metalloproteinases in development, repair, and destruction of the lungs[J]. Prog Mol Biol Transl Sci, 2017, 148: 1-29.
|
[20] |
Tian XY, Zhang XD, Li QL, et al. Biological markers in cord blood for prediction of bronchopulmonary dysplasia in premature infants[J].Clin Exp Obstet Gynecol, 2014, 41(3): 313-318.
|
[21] |
Lee C, An J, Kim JH, et al. Low levels of tissue inhibitor of metalloproteinase-2 at birth may be associated with subsequent development of bronchopulmonary dysplasia in preterm infants[J]. Korean J Pediatr, 2015, 58(11): 415.
|
[22] |
Alvira CM. Aberrant pulmonary vascular growth and remodeling in bronchopulmonary dysplasia[J]. Front Med (Lausanne), 2016, 3: 21-35.
|
[23] |
Berry MJ. The heart of the matter: a vascular hypothesis for bronchopulmonary dysplasia[J]. J Physiol (Lond), 2019, 597(4): 991-992.
|
[24] |
Ma XN, Li QP, Feng ZC. Research progress in cytokines and signaling pathways for promoting pulmonary angiogenesis and vascular development[J]. Chin J Contemp Pediatr, 2013, 15(9): 800-805.
|
[25] |
Eklund L, Kangas J, Saharinen P. Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems[J]. Clin Sci, 2017, 131(1): 87-103.
|
[26] |
Fagiani E, Christofori G. Angiopoietins in angiogenesis[J]. Cancer Lett, 2013, 328(1): 18-26.
|
[27] |
Biel NM, Siemann DW. Targeting the angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference[J]. Cancer Lett, 2016, 380(2): 525-533.
|
[28] |
Procianoy RS, Hentges CR, Silveira RC. Vascular endothelial growth factor/placental growth factor heterodimer levels in preterm infants with bronchopulmonary dysplasia[J]. Am J Perinatol, 2016, 33(5): 480-485.
|
[29] |
Kim DH, Kim HS. Serial changes of serum endostatin and angiopoietin-1 levels in preterm infants with severe bronchopulmonary dysplasia and subsequent pulmonary artery hypertension[J]. Neonatology, 2014, 106(1): 55-61.
|
[30] |
Mohamed WA, Niyazy WH, Mahfouz AA. Angiopoietin-1 and endostatin levels in cord plasma predict the development of bronchopulmonary dysplasia in preterm infants[J]. J Trop Pediatr, 2011, 57(5): 385-388.
|
[31] |
El Shemi MS, Tawfik S, Khafagy SM, et al. Endothelin 1 as a predictor marker for bronchopulmonary dysplasia in preterm neonates with respiratory distress syndrome[J]. J Neonatal Perinatal Med, 2017, 10(1): 79-83.
|
[32] |
Piersigilli F, Bhandari V. Biomarkers in neonatology: the new " omics" of bronchopulmonary dysplasia[J]. J Matern Fetal Neonatal Med, 2016, 29(11): 1758-1764.
|
[33] |
Lal CV, Ambalavanan N. Genetic predisposition to bronchopulmonary dysplasia[J]. Semin Perinatol, 2015, 39(8): 584-591.
|
[34] |
Yang Y, Qiu J, Kan Q, et al. MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and Meta-analysis[J]. Genet Mol Res, 2013, 12(4): 5195-5206.
|
[35] |
Lohmann P, Luna RA, Hollister EB, et al. The airway microbiome of intubated premature infants: characteristics and changes that predict the development of bronchopulmonary dysplasia[J]. Pediatr Res, 2014, 76(3):294-301.
|